Liquidity And Financial StrategyABCL is leveraging its large $800M+ liquidity position to cultivate an internal pipeline and high-value strategic partnerships.
Research And DevelopmentTransition from platform to pipeline continues with two significant therapeutic antibodies entering clinical trials.
Strategic PartnershipsAbCellera succeeded in signing two new partnerships in 2024, with Biogen and venture firms Viking and ArrowMark, and expanding two legacy programs.